Cyclic GMP-specific 3',5'-cyclic phosphodiesterase (PDE5)

Cyclic GMP-specific 3',5'-cyclic phosphodiesterase (abbreviated PDE5) is an enzyme responsible for the hydrolysis of cyclic guanosine monophosphate (cGMP) to 5'-GMP, thus regulating intracellular levels of cGMP. This enzyme is expressed in smooth muscle (including the corpus cavernosum, pulmonary vasculature, and to a lesser extent cardiac tissue), where it modulates vascular tone and contractility. PDE5 is the molecular target of widely used drugs for erectile dysfunction and pulmonary hypertension, such as sildenafil and tadalafil, due to its critical role in cGMP signaling. Inhibition of PDE5 leads to increased cGMP, promoting smooth muscle relaxation and vasodilation. Its dysregulation or altered activity has been implicated in cardiovascular disorders, right ventricular hypertrophy, and pulmonary vascular diseases.

Other names

Phosphodiesterase type 5PDE5AcGMP-specific phosphodiesterasePhosphodiesterase V

Inhibition of PDE5 increases intracellular cGMP, causing smooth muscle relaxation and vasodilation. Indirect reduction of cellular proliferation (vascular/cardiac smooth muscle). Modulation of contractile function in cardiac tissue.